Palvella Therapeutics Inc (PVLA) Actualités

Form 8-K - Current report

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

Publication reports 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the...